Semaglutide for Weight Loss: Complete Guide

Semaglutide has become the most-discussed weight loss medication in decades. It delivers results that previously required bariatric surgery. It also comes with real costs, genuine side effects, and clinical nuances that most marketing materials skip. This guide covers what semaglutide actually is, who benefits, what to expect, and how to think about whether it fits your situation.

What Semaglutide Is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your gut releases naturally when you eat. It tells your pancreas to release insulin, slows down how fast food leaves your stomach, and signals your brain that you are full. Semaglutide mimics this natural hormone but lasts much longer in the body, which is why it only needs to be injected once a week.

The same medication is sold under different brand names for different uses:

• Ozempic – FDA approved for type 2 diabetes. Often prescribed off-label for weight loss.
• Wegovy – FDA approved specifically for chronic weight management in adults with obesity or overweight plus at least one weight-related condition.
• Rybelsus – Oral form (pill) approved for type 2 diabetes. Less commonly used for weight loss because of lower absorption.

Chemically they are all the same drug. The differences are labeling, dosing conventions, and which indication insurance will cover.

How Semaglutide Produces Weight Loss

Semaglutide does not melt fat or block calorie absorption. It works upstream, by changing how hungry you feel and how full you stay. The mechanism has four distinct parts:

Reduced appetite signals in the brain. GLP-1 receptors in the hypothalamus regulate hunger. When semaglutide activates them, you feel less hungry between meals and satisfied with smaller portions.

Slower gastric emptying. Food stays in your stomach longer. This extends the “full” feeling from each meal and reduces the urge to snack.

Reduced food reward response. Many patients report that food becomes “less interesting” on semaglutide. The drive to seek out high-calorie foods specifically decreases. This is separate from pure appetite – it affects what you want to eat, not just how much.

Improved insulin sensitivity. Secondary effect relevant for metabolic health even if you are not diabetic.

The net result: most patients eat 500 to 1,000 fewer calories per day without conscious restriction. The weight loss follows naturally from the caloric deficit, not from any direct fat-burning effect of the medication itself.

What Results to Expect on Semaglutide for Weight Loss

The largest trial of semaglutide for weight loss is STEP 1, a 68-week study of 1,961 adults with obesity. The results:

A landmark STEP 1 trial published in the New England Journal of Medicine demonstrated that participants on semaglutide 2.4 mg weekly lost an average of 14.9 percent of their body weight over 68 weeks. Placebo group lost 2.4 percent. Roughly 86 percent of treated participants lost at least 5 percent of body weight, and 32 percent lost 20 percent or more.

Translated to real numbers: a 220-pound starting patient averaged losing 33 pounds. The top third lost 44 pounds or more. These are averages that assume sticking with the full protocol including lifestyle changes.

Real-world results tend to run slightly lower than trial averages because compliance is harder outside a research setting. A typical clinic patient at the full 2.4 mg weekly dose who stays on therapy for a year can expect 10 to 15 percent body weight loss, depending on lifestyle factors.

See our dedicated post on semaglutide results for a more detailed breakdown of what weight loss to expect at each phase.

Who Is a Good Candidate for Semaglutide?

Semaglutide is FDA-approved for weight management in adults who meet either criterion:

• BMI of 30 or higher (obesity)
• BMI of 27 or higher (overweight) plus at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, cardiovascular disease

In 2024 the FDA also expanded approval to include adolescents 12 and older with obesity.

Clinical judgment extends beyond FDA criteria. Many clinicians including Dr. Ashar consider semaglutide appropriate for patients with BMI 25-27 plus strong weight-related risk factors, even without formal obesity. What matters more than the BMI number is the overall clinical picture: metabolic risk, prior weight loss attempts, coexisting conditions, and medication tolerability.

Who Should Not Take Semaglutide

Absolute contraindications (must not use):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Severe allergy to semaglutide or any formulation component

Relative contraindications (use with caution):

• Active pancreatitis or history of severe pancreatitis
• Severe gastrointestinal disease including gastroparesis
• Severe kidney or liver impairment
• Currently pregnant or trying to conceive
• History of diabetic retinopathy (rapid glucose improvement can worsen early retinopathy)

These require clinical review before starting, not automatic exclusion. Some patients in the relative contraindication group can still take semaglutide safely under closer monitoring.

The Starting Protocol

Semaglutide requires dose titration. You do not start at the full therapeutic dose. Standard protocol:

• Month 1: 0.25 mg weekly
• Month 2: 0.5 mg weekly
• Month 3: 1.0 mg weekly
• Month 4: 1.7 mg weekly
• Month 5 onward: 2.4 mg weekly (maintenance dose for weight loss)

The graduated increase exists because rapid dose escalation increases the risk of severe nausea, vomiting, and gastrointestinal intolerance. Most patients who fail semaglutide fail at the escalation stages, not at the maintenance stage. Going slower through titration is usually the right call when side effects are intense.

Some patients stay on a lower dose long-term if their weight loss is progressing at 1.7 mg and side effects are manageable. Going to the maximum dose is not mandatory if a lower dose is working.

Side Effects You Should Know About

Gastrointestinal side effects are the most common and affect most patients at some point:

• Nausea – 20 to 50 percent of patients, most common during dose increases, usually manageable
• Diarrhea or constipation – Either can occur, typically improves with time
• Vomiting – More common early, usually subsides
• Reduced appetite – This is the therapeutic effect, but can be excessive in some patients
• Fatigue – Related to reduced caloric intake, usually improves as the body adjusts

Less common but important:

• Pancreatitis (rare but requires immediate evaluation if severe abdominal pain occurs)
• Gallbladder disease including gallstones
• Kidney injury from dehydration (maintain hydration during GI symptoms)
• Injection site reactions (usually minor and transient)

The most important principle: if side effects are severe at any dose, the right response is to delay the next dose increase, not push through. Semaglutide is a marathon, not a sprint. Many patients plateau at a middle dose and do well there.

Long-Term Safety

Semaglutide has been in clinical use since 2017 for diabetes and 2021 for weight loss. The long-term safety profile is still emerging but has been reassuring in follow-up studies.

A cardiovascular outcomes trial published in the New England Journal of Medicine (SELECT trial) followed 17,604 participants over a mean of 40 months and found that semaglutide reduced major cardiovascular events by 20 percent in patients with overweight or obesity and pre-existing cardiovascular disease. This was the first clear evidence that weight loss medication produces cardiovascular benefit independent of diabetes treatment.

The FDA’s ongoing postmarketing surveillance of GLP-1 medications has not identified new major safety signals beyond what was known at approval. The most-watched concerns remain thyroid C-cell tumors (seen in rats but not clearly demonstrated in humans), pancreatitis, and gallbladder disease. None have emerged as common problems in the general prescribing population.

The Cost Reality

Brand-name semaglutide is expensive. Without insurance, Wegovy runs approximately 1,350 dollars per month at retail pharmacies. Ozempic (same drug, different label) runs slightly less, around 1,000 dollars monthly.

Coverage varies widely. Some commercial insurance plans cover Wegovy for weight loss under prior authorization requirements. Many do not. Medicare covers Ozempic for diabetes but not weight loss as of 2025.

Compounded semaglutide through licensed pharmacies typically costs 200 to 400 dollars per month. Quality varies by source – some compounded products are excellent and some are problematic.

See our dedicated posts on semaglutide cost and compounded vs brand comparison for specific pricing and decision frameworks.

What Happens When You Stop

This is the part most patients do not fully grasp at the start: the weight comes back if you stop without a plan.

A follow-up study of STEP 1 trial participants found that patients regained roughly two-thirds of lost weight within a year of stopping semaglutide, even with continued lifestyle counseling. The appetite suppression effect disappears within weeks. Old hunger patterns return.

This means semaglutide should be approached as either a long-term treatment or a short-term intervention followed by a structured maintenance plan including possible lower-dose continuation, tirzepatide transition, or aggressive behavioral protocols. Stopping cold turkey without a plan is the most common cause of full weight regain.

See our post on what happens when you stop semaglutide for the weight regain data and exit planning strategies.

How to Think About Whether Semaglutide Is Right for You

Good candidates for semaglutide typically share these features:

1. BMI qualifies them under FDA criteria or clinical judgment
2. They have tried lifestyle changes without success or with insufficient success
3. They are willing to commit to weekly injections for at least 12 to 18 months
4. They can afford the medication (brand, compounded, or through coverage)
5. They have a plan for maintenance after primary weight loss phase
6. They do not have absolute contraindications
7. They can tolerate or manage GI side effects

Less ideal candidates for semaglutide:

1. Small amount of weight to lose (less than 10 pounds) – risk/benefit often not favorable
2. Major GI disease history
3. Expectation of quick fix without long-term commitment
4. Unable to afford continuation of therapy or maintenance
5. Severe eating disorder history without specialty management

The clinical evaluation at Tactus Health covers all these factors plus labs (A1C, comprehensive metabolic panel, lipid panel, thyroid function) to ensure semaglutide is appropriate and to establish baseline metrics for monitoring progress.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Medical Director at Tactus Health. Dual board-certified nurse practitioner specializing in medical weight loss, hormone therapy, and metabolic health. Sugar Hill, GA with telehealth for Georgia patients.